Latest 10-Q quarterly reports

Presidio Production Company reports Q1 2026 financial results following its recent business combination and acquisition of EQV Resources.

Wetouch Technology reports Q1 2026 net income of $3.9 million, a 50% increase year-over-year, driven by higher revenues and reduced administrative expenses.

Artisan Consumer Goods reports zero revenue and a continued going concern warning as it seeks a new manufacturer for its granola brand.

GSR IV Acquisition Corp. reports Q1 2026 financial results as it continues its search for an initial business combination.

Infinite Eagle Acquisition Corp. reports its Q1 2026 financial results following the completion of its initial public offering.

Vertical Data Inc. reports Q2 2026 financial results, highlighting a $1.33 million net loss and significant customer prepayments.

Family Office of America reported a net profit of $263,789 for Q1 2026, driven by recent acquisitions of accounting service firms.

SUNation Energy reports a significant decline in Q1 2026 revenue and initiates a strategic review process to explore potential sale or merger options.

Blue Dolphin Energy Company reports a significant increase in Q1 2026 net income to $14.7 million, driven by improved gross margins despite ongoing debt defaults.

Plus Therapeutics reports Q1 2026 financial results, highlighting progress in clinical trials and diagnostic commercialization.

Exzeo Group, Inc. filed an amendment to its Q1 2026 quarterly report to correct technical errors in tabular financial disclosures.

Athena Technology Acquisition Corp. II reports Q1 2026 results while advancing its pending business combination with Ace Green Recycling.

Nu Ride Inc. reports Q1 2026 financial results, highlighting ongoing litigation efforts and strategic asset management following its emergence from Chapter 11 bankruptcy.

Calisa Acquisition Corp reports Q1 2026 results while progressing toward its business combination with Goodvision AI Inc.

Outlook Therapeutics reports Q2 2026 financial results, highlighting ongoing commercialization in Europe and continued regulatory efforts for ONS-5010 in the U.S. amid going concern warnings.

Quest Patent Research Corporation reports a net loss of $2.9 million for Q1 2026 with no revenue generated during the period.

Inflection Point Acquisition Corp. V reports Q1 2026 financial results while continuing to pursue its business combination with GOWell Technology Limited.

Pasithea Therapeutics reports a net loss of $2.9 million for Q1 2026 as it continues clinical development of its lead candidate, PAS-004.

Annovis Bio reports a net loss of $17.6 million for Q1 2026 as it advances its lead neurodegeneration candidate, buntanetap, through pivotal clinical trials.

Graf Global Corp. reports Q1 2026 financial results as it continues its search for an initial business combination.

QS Energy reports a net loss of $781,000 for Q1 2026 while continuing to face substantial doubt regarding its ability to continue as a going concern.

LightWave Acquisition Corp. reports Q1 2026 net income of $1.76 million, driven by interest income from its trust account while continuing its search for a business combination.

Permianville Royalty Trust reports Q1 2026 distributable income of $1.4 million, driven by increased natural gas production.

Bold Eagle Acquisition Corp. reports Q1 2026 financial results as it continues its search for an initial business combination before the October 2026 deadline.

Solana Company reports a $99.8 million net loss for Q1 2026 driven by digital asset volatility and announces a major executive leadership transition.

Forum Markets reports a net loss of $76.3 million for Q1 2026 as it transitions to a digital asset and RWA tokenization business model.

Metal Sky Star Acquisition Corporation reports a net loss of $113,689 for Q1 2026 while continuing efforts to finalize a business combination.

Mesa Royalty Trust reports a significant decline in quarterly distributable income to $601, down from $80,999 in the prior year period.

Suncrete, Inc. reports a net loss for Q1 2026 but highlights the successful consummation of its business combination and several strategic acquisitions expanding its footprint in the Southern U.S.

Ensysce Biosciences reported a significant increase in net loss and cash burn for Q1 2026, raising substantial doubt about its ability to continue as a going concern.